These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31431452)

  • 1. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
    Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
    Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
    Montvida O; Green JB; Atherton J; Paul SK
    Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
    J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
    Chou HC; Chen WW; Hsiao FY
    Drug Saf; 2014 Jul; 37(7):521-8. PubMed ID: 24859164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
    Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
    J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic Safety of Sitagliptin in the TECOS Study.
    Buse JB; Bethel MA; Green JB; Stevens SR; Lokhnygina Y; Aschner P; Grado CR; Tankova T; Wainstein J; Josse R; Lachin JM; Engel SS; Patel K; Peterson ED; Holman RR;
    Diabetes Care; 2017 Feb; 40(2):164-170. PubMed ID: 27630212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
    Hong JL; Buse JB; Jonsson Funk M; Pate V; Stürmer T
    Diabetes Care; 2018 Jun; 41(6):1196-1203. PubMed ID: 29618573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
    BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
    Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
    Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
    Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
    Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis.
    Kim MK; Han K; Kwon HS; Yoo SJ
    Endocrinol Metab (Seoul); 2023 Aug; 38(4):426-435. PubMed ID: 37469033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.